ArticleInternational journal of women's health2026
Patient Selection Metrics and Efficacy of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Analysis.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate risk factors of overall survival (OS) in patients with advanced epithelial ovarian cancer (AEOC) and establish predictive models for predicting postoperative complete cytoreduction (R0 resection) in AEOC patients to guide individualized treatment (PDS or NACT-IDS). Material and Methods: This retrospective analysis of 818 AEOC patients treated at Qilu Hospital of Shandong University between January 2014 and December 2023 compared survival outcomes (OS, PFS) and R0 rates following PDS vs. NACT-IDS using Cox regression and Kaplan-Meier methods. Based on the PDS and NACT-IDS group, two predictive models were established using logistic regression analysis to predict postoperative R0 resection. Results: Patients undergoing NACT-IDS treatment have a heavier tumor burden and a higher R0 resection rate (56.40% vs 39.90%, Conclusion: Complete cytoreduction remains the most critical determinant of survival in AEOC. Preoperative models combining CA153 and the Suidan score provide practical tools to support individualized selection of PDS or NACT-IDS strategies. Clinical Trial Number: ChiCTR2600116858.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.